摘要
目的探讨18F-FDG PET/CT显像对评估淋巴瘤疗效的价值。方法收集2010年3月至2013年4月确诊为淋巴瘤并行放化疗治疗的20例患者的临床资料,所有病例均随访1个月以上。结果 20例患者中9例在治疗过程中行PET/CT检查,提示代谢减低30%以上者预后良好,且代谢降低越早、越多,预后越好;11例在治疗结束后行PET/CT检查,9例阴性者仅1例复发,而2例阳性者全部复发。结论 18F-FDG PET/CT显像能很好地评价淋巴瘤的治疗效果,且可早期预测治疗效果及预后。
Objective To evaluate the value of 18F-FDG PET/CT imaging in evaluating the response to treatment of lymphoma.Methods Clinical data of 20patients who were diagnosed with lymphoma and treated with chemoradiotherapy between March 2010and Arpil 2013were collected.All cases were followed up for more than 1month.Results Among the 20patients,9received PET/CT examination during treatment.Patients with a decrease in metabolism by more than 30% had a good prognosis.Furthermore,the earlier and the more the metabolism decreased,the better the prognosis was.Among the 11patients who received PET/CT examination after treatment,results were negative in 9.The recurrence occurred in 1negative case and 2positive cases.Conclusion The 18F-FDG PET/CT imaging can evaluate and predict the therapeutic effect and prognosis in lymphoma.
出处
《南昌大学学报（医学版）》
CAS
2013年第8期16-18,共3页
Journal of Nanchang University：Medical Sciences
基金
江西省卫生厅科技计划(20133006)
